ClinicalTrials.gg
Active, not recruitingNCT05296447Updated Nov 6, 2026

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy

A Phase 2 interventional study of Standard of Care and Aflibercept in Diabetic Retinopathy, DR, sponsored by AbbVie. Active, not recruiting at 20 sites in United States. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Updated Nov 6, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing aflibercept in Diabetic Retinopathy — 2 open to participants now, 4 under way, none of them phase 3. aflibercept · Diabetic Retinopathy.

Enrollment
5th of 21
103 · median 38
Started
2022
the only one that year
Phase 2
7 of 21
none open now
Registered
16th of 21
by date
Lead sponsor
1 of 21
AbbVie

Among the 21 studies testing aflibercept in Diabetic Retinopathy, this one is the 5th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 2, and was the 16th registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 21 studies testing aflibercept in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing aflibercept in Diabetic Retinopathy, or all of them as a file.
02

Study summary

This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic macular edema (CI-DME) in which they received suprachoroidal space (SCS) administration of ABBV-RGX-314. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early discontinuation visit in the previous (parent) clinical study. Participants will be followed for a total of 5 years post-ABBV-RGX-314 administration (inclusive of the parent study). As such, the total study duration for each participant may vary depending on when they enroll in the current study following ABBV-RGX-314 administration in the parent study.

03

Conditions studied

  • Diabetic Retinopathy, DR

Browse trials for

Keywords

  • Diabetic Retinopathy, DR
  • Gene Therapy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must provide written, signed for this study
  • Must have been enrolled in a previous clinical study of ABBV-RGX-314 for the treatment of DR with or without CI-DME and must have received an SCS injection of ABBV-RGX-314 in that study
  • Must be willing and able to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Other
    Standard of Care

    Dose Level (DL) 1-3 participants who received ABBV-RGX-314 in a parent study will continue to receive standard of care for the study duration.

    Drug: Standard of Care

  • Other
    Supplemental Treatment

    DL4 participants from parent study will be eligible to receive supplement aflibercept through a prespecified timepoint based on protocol-specified criteria if they develop worsening CI-DME or high-risk proliferative diabetic retinopathy (PDR) in the study eye.

    Drug: Standard of Care · Drug: Aflibercept

Interventions

  • DrugStandard of Care

    Standard of Care

  • Injection

    Also known as: EYLEA

06

What researchers measure

Primary outcomes

  1. Incidence of ocular adverse events (AEs) and any serious adverse events (SAEs)

    To evaluate the long-term safety of ABBV-RGX-314

    Time frame: 5 years inclusive of the parent study

Secondary outcomes

  1. Incidences of non-ocular AEs and any Adverse Events of Special Interest

    Time frame: 5 years, inclusive to the parent study

  2. Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in DR by ETDRS-DRSS on digital stereoscopic fundus photography

    Time frame: 5 years, inclusive of the parent study

  3. Proportion of participants achieving 0-step (no change), a ≥1-step, a ≥2-step, or a ≥3-step or greater change in DR per ETDRS-DRSS on digital stereoscopic fundus photography from baseline (ie, prior to ABBV-RGX-314 administration in the parent study)

    Time frame: 5 years, inclusive to the parent study

  4. Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in BCVA

    Time frame: 5 years, inclusive to the parent study

  5. Proportion of participants gaining or losing ≥ 5, 10, and 15 letters in BCVA compared with baseline (ie, prior to ABBV-RGX-314 administration in the parent study)

    Time frame: 5 years, inclusive to the parent study

  6. Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in CST as measured by SD-OCT

    Time frame: 5 years, inclusive to the parent study

  7. Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in the area of retinal nonperfusion on ultra-widefield Optos FA

    Time frame: 5 years, inclusive to the parent study

  8. Proportion of participants requiring any additional intervention for ocular diabetic complications (eg, anti-VEGF intravitreal injection or PRP)

    Time frame: 5 years, inclusive to the parent study

  9. Mean number of anti-VEGF injections through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)

    Time frame: 5 years, inclusive to the parent study

  10. Mean number of anti-VEGF injections in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)

    Time frame: 5 years, inclusive to the parent study

  11. Mean anti-VEGF injection annualized rate through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)

    Time frame: 5 years, inclusive to the parent study

  12. Mean anti-VEGF injection annualized rate in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)

    Time frame: 5 years, inclusive to the parent study

  13. Proportion of participants with any sight-threatening ocular diabetic complications

    Time frame: 5 years, inclusive to the parent study

  14. Mean number of retina specialist visits attended for complications of DR based on chart review

    Time frame: 5 years, inclusive to the parent study

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Jun 2031, 110 months after the start.

Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's planned 110 months is above that.

Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2022
First posted
Mar 25, 2022
StartActual
Apr 4, 2022
Primary completionEst.
Jun 2031
CompletionEst.
Jun 2031
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Nov 6, 2026
Enrollment
100 (estimated)→103 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Enrolling by invitation→Active, not recruiting
    Enrollment 100 (estimated)→103 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05296447
Lead sponsor
AbbVie
Collaborators
REGENXBIO Inc.
Responsible party
Sponsor
First posted
Mar 25, 2022
Start date
Apr 4, 2022
Primary completion
Jun 2031 (estimated)
Completion
Jun 2031 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion